Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93


Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.

Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J; WHI Investigators.

JAMA. 2017 Sep 12;318(10):927-938. doi: 10.1001/jama.2017.11217.


The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic review.

Siyam T, Ross S, Campbell S, Eurich DT, Yuksel N.

BMC Womens Health. 2017 Mar 21;17(1):22. doi: 10.1186/s12905-017-0370-6. Review.


Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.

Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, Stanczyk FZ, Selzer RH, Azen SP; ELITE Research Group.

N Engl J Med. 2016 Mar 31;374(13):1221-31. doi: 10.1056/NEJMoa1505241.


Associations of sex steroid hormones with mortality in women with breast cancer.

Duggan C, Stanczyk F, Campbell K, Neuhouser ML, Baumgartner RN, Baumgartner KB, Bernstein L, Ballard R, McTiernan A.

Breast Cancer Res Treat. 2016 Feb;155(3):559-67. doi: 10.1007/s10549-016-3704-4. Epub 2016 Feb 10.


The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk.

Flores VA, Taylor HS.

Endocrinol Metab Clin North Am. 2015 Sep;44(3):587-602. doi: 10.1016/j.ecl.2015.05.007. Epub 2015 Jun 23. Review.


Invasive Breast Cancer Incidence in 2,305,427 Screened Asymptomatic Women: Estimated Long Term Outcomes during Menopause Using a Systematic Review.

Cutler W, Bürki R, Kolter J, Chambliss C, Friedmann E, Hart K.

PLoS One. 2015 Jun 24;10(6):e0128895. doi: 10.1371/journal.pone.0128895. eCollection 2015. Review. Erratum in: PLoS One. 2015;10(8):e0135432.


Bias in Observational Studies of the Association between Menopausal Hormone Therapy and Breast Cancer.

Zahl PH, Mæhlen J.

PLoS One. 2015 May 4;10(5):e0124076. doi: 10.1371/journal.pone.0124076. eCollection 2015.


Menopausal hormone therapy and breast cancer mortality: clinical implications.

Chlebowski RT, Anderson GL.

Ther Adv Drug Saf. 2015 Apr;6(2):45-56. doi: 10.1177/2042098614568300. Review.


Lobular breast cancer: incidence and genetic and non-genetic risk factors.

Dossus L, Benusiglio PR.

Breast Cancer Res. 2015 Mar 13;17:37. doi: 10.1186/s13058-015-0546-7. Review.


Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes.

Bassuk SS, Manson JE.

Ann Epidemiol. 2015 Mar;25(3):193-200. doi: 10.1016/j.annepidem.2014.11.004. Epub 2014 Nov 13.


Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke.

Prentice RL.

Semin Reprod Med. 2014 Nov;32(6):419-25. doi: 10.1055/s-0034-1384624. Epub 2014 Oct 16. Review.


Menopausal hormone therapy and cancer: changing clinical observations of target site specificity.

Chlebowski RT, Anderson GL.

Steroids. 2014 Nov;90:53-9. doi: 10.1016/j.steroids.2014.06.001. Epub 2014 Jun 6. Review.


Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects.

Zhao S, Chlebowski RT, Anderson GL, Kuller LH, Manson JE, Gass M, Patterson R, Rohan TE, Lane DS, Beresford SA, Lavasani S, Rossouw JE, Prentice RL.

Breast Cancer Res. 2014 Mar 26;16(2):R30. doi: 10.1186/bcr3632.


Prescribing menopausal hormone therapy: an evidence-based approach.

Sood R, Faubion SS, Kuhle CL, Thielen JM, Shuster LT.

Int J Womens Health. 2014 Jan 11;6:47-57. doi: 10.2147/IJWH.S38342. eCollection 2014. Review.


The tissue selective estrogen complex: a promising new menopausal therapy.

Komm BS, Mirkin S.

Pharmaceuticals (Basel). 2012 Sep 4;5(9):899-924. doi: 10.3390/ph5090899.


Hormonal therapy and risk of breast cancer in mexican women.

Amadou A, Fabre A, Torres-Mejía G, Ortega-Olvera C, Angeles-Llerenas A, McKenzie F, Biessy C, Hainaut P, Romieu I.

PLoS One. 2013 Nov 15;8(11):e79695. doi: 10.1371/journal.pone.0079695. eCollection 2013.


Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB.

JAMA. 2013 Oct 2;310(13):1353-68. doi: 10.1001/jama.2013.278040.


Sex hormone levels and risk of breast cancer with estrogen plus progestin.

Farhat GN, Parimi N, Chlebowski RT, Manson JE, Anderson G, Huang AJ, Vittinghoff E, Lee JS, Lacroix AZ, Cauley JA, Jackson R, Grady D, Lane DS, Phillips L, Simon MS, Cummings SR.

J Natl Cancer Inst. 2013 Oct 2;105(19):1496-503. doi: 10.1093/jnci/djt243. Epub 2013 Sep 16.


Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.

Wood CE, Branstetter D, Jacob AP, Cline JM, Register TC, Rohrbach K, Huang LY, Borgerink H, Dougall WC.

Breast Cancer Res. 2013;15(4):R62.

Supplemental Content

Support Center